AbbVie bids to join the BCMA crowd with etentamig
AbbVie has filed for FDA approval of its BCMAxCD3 bispecific etentamig in multiple myeloma, a key pillar of its expansion into oncology.
Newsletters and Deep Dive digital magazine
AbbVie has filed for FDA approval of its BCMAxCD3 bispecific etentamig in multiple myeloma, a key pillar of its expansion into oncology.
Bayer's oral Factor XIa inhibitor asundexian has been cleared in its first market, China, for secindary stroke prevention.
China has emerged as a major source of drug candidates for pharma groups, but a new proposal by the US Treasury could slam the brakes on future deals.
NICE has backed temporary NHS use of five AI tools that can help detect prostate cancer on MRI scans, while more evidence on their value is gathered.
AstraZeneca has staked a claim to the increasingly crowded IgAN market with an accelerated approval from the FDA for Ultomiris, its fifth indication.
Editor's Picks
Newsletters and Deep Dive
digital magazine